Highest-materiality recent filing
BD resumes ChloraPrep shipments after voluntary hold; all final release testing acceptable
BD voluntarily placed ChloraPrep and PurPrep on ship hold on May 6, 2026 for additional final release testing.
Revenue $4,714M, +5.2% reported/2.6% FX-neutral; GAAP diluted EPS $(0.13) from continuing ops vs $0.55 prior year.
BD EVP & Interventional President Richard Byrd to retire in June 2026
Richard Byrd, EVP and President of Interventional segment, will retire after nearly 25 years at BD; will stay in role through June.
BD files recast financials to reflect Feb 2026 spin-off of Biosciences & Diagnostics
Recast historical data presents continuing operations only, excluding the spun-off Biosciences and Diagnostic Solutions business.
BD upsizes senior notes tender to $2B, announces early results and pricing
Upsized aggregate offer cap from $1.6B to $2.0B; early tenders exceeded cap, triggering proration on 3.794% notes due 2050.
BD launches $1.6B tender offers for 15 series of senior notes
Up to $1.6B aggregate purchase price (excluding accrued interest) for 15 series of senior notes maturing 2026-2050.
BD completes spin-off of Biosciences & Diagnostic Solutions business and combination with Waters
BD completed spin-off of Biosciences & Diagnostic Solutions business and combination with Waters, receiving $4 billion cash.
BD Q1 revenue $5.25B beats; closes Waters deal; affirms FY26 guidance
Revenue $5.252B (+1.6% reported, +0.4% FX neutral); GAAP EPS $1.34, adjusted EPS $2.91.
Filed Certificate of Designation for Series D Junior Participating Redeemable Preferred Stock.
BD Q4 revenue $5.9B (+8.3%); FY25 adjusted EPS $14.40 (+9.6%); FY26 guidance
Q4 revenue $5,890M, up 8.3% as reported, 3.9% organic; GAAP EPS $1.72, adjusted EPS $3.96.
BD reports prelim Q4 rev $5.9B (+8.3%); CFO DelOrefice to depart Dec 5; Roque interim CFO
Preliminary Q4 revenue ~$5.9B, up 8.3% reported, 3.9% organic; FY revenue ~$21.8B, up 8.2% reported, 2.9% organic.
BD Q3 revenue $5.5B (+10.4%); adjusted EPS $3.68; raises FY guidance to $14.30-$14.45
Revenue of $5.5B, up 10.4% as reported and 3.0% organic; GAAP EPS $2.00, adjusted EPS $3.68.
BD to combine its Biosciences & Diagnostic Solutions with Waters in ~$17.5B RMT transaction
Transaction valued at ~$17.5B; BD shareholders to own ~39.2% of combined company; Waters ~60.8%.
BD to spin off Biosciences/Diagnostics, merge with Waters for $4B cash plus 39.2% stake
BD receives $4B cash from SpinCo; BD shareholders get 39.2% of Waters post-merger; Waters holders get 60.8%.
BD Q2 fiscal 2025: Revenue $5.27B (+4.5%), GAAP EPS $1.07 (down 42% YoY), adj. EPS $3.35
Revenue increased 4.5% as reported to $5.272B; organic growth 0.9%, currency-neutral growth 6.0%.
BD beats Q1 estimates, announces plan to separate Biosciences and Diagnostic Solutions
Q1 revenue $5.2B (+9.8% reported, +3.9% organic); adj. EPS $3.43 (+28.0% YoY); GAAP EPS $1.04.
Q4 revenue $5.4B, +6.9% as reported; GAAP EPS $1.45 (vs $0.53), adjusted EPS $3.81 (vs $3.42).
Settlement covers cases in Rhode Island consolidated litigation and federal MDL in Ohio; no admission of liability.
BD Q3 adjusted EPS $3.50 beats, raises FY24 guidance; acquires Edwards Critical Care for $4.2B
Revenue $4.99B as reported, $5.057B adjusted; organic revenue growth 5.2% YoY.
Becton Dickinson extends $2.75B revolving credit facility maturity to September 2027
Lenders consented to one-year extension of commitment termination date to September 24, 2027.
BD issues €1.8B + $600M notes to fund Edwards Critical Care acquisition
€1.0B 3.828% notes due 2032, €800M 4.029% notes due 2036, $600M 5.081% notes due 2029 issued June 7.
BD to acquire Edwards Lifesciences' Critical Care for $4.2B in cash
Acquisition price of $4.2B in cash; expected to close by end of calendar 2024, subject to regulatory approvals.
BD Q2 revenue $5.0B (+4.6%), adj. EPS $3.17 (+10.8%); raises FY24 adjusted EPS guidance
Q2 revenue $5,045M (+4.6% reported, +5.7% organic); GAAP diluted EPS $1.85 (+20.9%), adjusted EPS $3.17 (+10.8%).
BD issues $1.175B USD notes and €750M EUR notes to refinance 2024 maturities
$625M 4.874% notes due 2029 and $550M 5.110% notes due 2034 issued in USD offering.
BD Q1 revenue $4.7B (+2.6% YoY), GAAP EPS $0.96, adj. EPS $2.68; raises FY2024 guide
Q1 revenue $4,706M, up 2.6% as reported, 2.4% organic; currency-neutral growth 1.6%.
BD Q4 revenue $5.1B up 6.8%; adjusted EPS $3.42 beats; guides FY24 organic growth 5.75%
Q4 revenue of $5.1B, +6.8% as reported, +5.9% currency-neutral; base business organic growth 7.0%.
BD Q3 revenue $4.88B up 5.1%, adjusted EPS $2.96 up 11.3%, raises FY revenue guidance
Revenue of $4.88B, up 5.1% as reported, 6.3% currency-neutral; base revenue growth 6.7% as reported.
Effective May 7, 2026 (the “Effective Date”), the Company’s Board of Directors (the “Board”) approved the appointment of Mr. Roque as the Company’s Executive Vice President and Chief Financial Officer.
Effective March 26, 2025, Gregory J. Hayes was elected to the Board of Directors (the “Board”) of Becton, Dickinson and Company (“BD”).
On January 9, 2025, the Board of Directors (the “Board”) of Becton, Dickinson and Company (the “Company”) appointed Pamela L. Spikner as Senior Vice President, Chief Accounting Officer and Controller, effective January 20, 2025.
Christopher DelOrefice, Executive Vice President and Chief Financial Officer, will assume the responsibilities of principal accounting officer on an interim basis.
Thomas Spoerel will serve as the Senior Vice President, CFO Regions along with finance leadership for the finance integration of the recently announced agreement for Becton Dickinson to acquire the Edwards Life Sciences’ Critical Care product group.
On February 22, 2024, David Hickey, Executive Vice President and President of the Life Sciences segment of Becton, Dickinson and Company ("BD"), informed BD of his intention to retire, effective July 1, 2024.
On July 24, 2023, Dr. Joanne Waldstreicher was elected to the Board of Directors of Becton, Dickinson and Company.
On December 30, 2022, Samrat S. Khichi, Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel, informed BD of his intent to depart BD for a new opportunity, effective February 3, 2023.
Michael Garrison has been named BD's Executive Vice President and President, Medical Segment
Richard Byrd has been named BD's Executive Vice President and President, Interventional Segment
Simon Campion informed BD that he will depart BD on September 9, 2022 for an executive role in the health care industry.
each of Claire Pomeroy, MD and David F. Melcher has resigned as directors of BD, in each case effective as of April 1, 2022, in connection with the completion of the Separation and the Distribution and their appointment to the board of directors of embecta.
Max materiality 1.00 · Median 0.60 · Most common event earnings